
Antibiotics Pre-Appendectomy Don't Lower Perforation Risk
Antibiotic treatment while awaiting appendectomy does not lower risk for appendiceal perforation in patients with uncomplicated acute appendicitis, according to a new study.
While the percentage of surgical site infections (SSIs) was small for both groups, patients who received antibiotics during the waiting period had lower rates of these infections.
The trial — titled PERFECT-Antibiotics — was a substudy embedded in a larger PERFECT clinical trial, which aimed to determine whether an in-hospital delay of appendectomy resulted in increased risk for appendiceal perforation when compared to emergent surgery.
The trial 'concluded that appendectomy does not need to be performed promptly in acute uncomplicated appendicitis and can be scheduled within 24 hours without increasing complications,' senior author Panu Mentula, MD, of the department of Gastroenterological Surgery, Helsinki University Hospital, Helsinki, Finland, and colleagues wrote in the study. 'The next question is whether preoperatively started antibiotic treatment reduces the risk of appendiceal perforations.'
The findings were published online in JAMA Surgery on May 14, 2025.
Trial Design
PERFECT-Antibiotics was an open-label, randomized trial conducted at two hospitals in Finland and one hospital in Norway. Researchers enrolled 1774 individuals diagnosed with acute uncomplicated appendicitis, diagnosed clinically or via imaging. Patients were placed in one of two groups: The antibiotic group received intravenous (IV) cefuroxime (1500 mg) and metronidazole (500 mg) every 8 hours until surgery, while the nonantibiotic group waited for surgery without antibiotics.
All patients received one dose of IV cefuroxime (1500 mg) and metronidazole (500 mg) during anesthesia induction. The primary outcome was perforated appendicitis and secondary outcomes included complication rate and SSIs within 30 days of follow-up.
The median age of patients was 35 years (interquartile range [IQR], 28-46 years), and 55% of patients were men. Patients waited a median time of 9 hours (IQR, 4.3-15.5) from study randomization to undergoing surgery.
No Difference in Appendiceal Perforation
Of the 888 patients in the preoperative antibiotic group, 26.2% received one dose, 38.7% received two doses, 22.6% received three doses, and 11.8% received four or more doses of antibiotics, including the antibiotic dose given during anesthesia. A total of 74 patients (8.3%) in this group had a perforated appendix.
Of the 886 patients not given preoperative antibiotics, 79 (8.9%) had a perforated appendix, which met the predetermined noninferiority threshold.
The groups had similar complication rates over the 30-day follow-up, though SSIs were lower in the antibiotic group (1.6%) than the no antibiotic group (3.2%).
The researchers estimated that the number needed to treat for antibiotic therapy was 63 for SSIs, 83 for intra-abdominal SSI, and 125 for reintervention.
'Although longer preoperative antibiotic treatment resulted in slightly lower rate of postoperative infectious complications, the actual difference was very small and probably clinically not significant to justify longer preoperative antibiotic treatment,' Mentula and colleagues wrote.
Lower Infection Rates With Antibiotics
Commenting on the study for Medscape Medical News , Theodore Pappas, MD, professor of surgery at Duke University School of Medicine in Durham, North Carolina, placed greater importance on these secondary outcomes.
Intra-abdominal infections, a subset of SSIs, were more than twice as common in the no-antibiotic group (1.9%) than in the antibiotic group (0.7%; P = .02). Positive blood cultures were also more common in the no-antibiotic group than the antibiotic group ( P = .02).
While the authors qualified these results, 'the reality was it was better to use antibiotics,' he said.
There was also a 'big overlap between the two groups,' he said, which may have muted differences between the two groups. For example, one fourth of patients in the antibiotic group received only one dose of antibiotics, the same treatment regimen as the no-antibiotic group.
'Although protocol required prophylaxis in all patients in the induction of anesthesia, some clinicians thought that it was unnecessary, because antibiotics had already been given only a couple of hours ago' in patients in the antibiotic group, Mentula told Medscape Medical News . She did not think that would affect the study's results.
The PERFECT trial and the antibiotics subtrial answer two important questions that have been asked for years, Pappas continued: Whether appendectomy for uncomplicated acute appendicitis needs to be performed emergently and if antibiotics administered while waiting for surgery improve outcomes.
'Basically, the study shows that you probably should keep them on antibiotics while you're waiting,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
10 hours ago
- Yahoo
Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025
TURKU, FI / / June 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r HR-MDS patients (n=32) treated with bexmarilimab + azacitidine; mOS of 9.3 months in TP53 mutated patients (n=13) ORR of 85% and cCR of 50% in patients with frontline MDS (n=20) Deep bone marrow responses demonstrated at all dose levels in frontline MDS and based on the safety and efficacy data of the trial, the recommended phase III bexmarilimab dose is 3 mg/kg Turku, Finland- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company advancing next-generation immunotherapies, presents detailed phase II data from its ongoing BEXMAB study evaluating bexmarilimab in high-risk myelodysplastic syndromes (HR-MDS) as an oral presentation at the 30th European Hematology Association's (EHA) Congress, taking place in Milan from 12-15 June 2025. The presentation will be led by Dr. Mika Kontro, Associate Professor at University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, and will contain detailed results from the study of bexmarilimab, Faron's investigational anti-Clever-1 antibody, in combination with azacitidine for patients with relapsed or refractory (r/r) and frontline or treatment-naïve HR-MDS. These results expand upon those presented at ASCO 2025 and reaffirm the efficacy and safety of bexmarilimab in this difficult-to-treat population. Strong efficacy data in both r/r HR-MDS and frontline MDS, support advancement into phase III The BEXMAB study evaluated bexmarilimab (1, 3, or 6 mg/kg weekly in 28-day cycles), a first-in-class monoclonal antibody targeting the Clever-1 receptor, in combination with azacitidine, a standard-of-care hypomethylating agent (HMA). By blocking Clever-1, bexmarilimab reprograms macrophages in the bone marrow, enhancing anti-tumor immunity. With 80% of patients with r/r HR-MDS (n=32) falling in the very high/high risk category at baseline, the phase II BEXMAB data demonstrated an estimated median overall survival (mOS) of approximately 13.4 months, significantly surpassing historical outcomes of 5-6 months expected under standard of care. A mOS of 9.3 months was observed in patients with the aggressive mTP53 mutation (n=13). Five patients in the r/r HR-MDS group proceeded to stem cell transplant (SCT), the only curative option. Of the non-mTP53 mutated patients mOS has not yet been reached and 15 out of 19 patients are still alive. Dr. Mika Kontro, MD, PhD, also the principal investigator of the BEXMAB study, said, "The consistent and durable responses observed with bexmarilimab are notable in this patient population. The survival data with bexmarilimab are encouraging for r/r HR-MDS patients, who have limited treatment options after failing HMA therapy." In an updated analysis compared to the ASCO data, patients with frontline MDS (n=20; 45% with the TP53 mutation), the combination of bexmarilimab with azacitidine demonstrated an ORR of 85% and a cCR of 50%. In those with TP53, the ORR and cCR were 78% and 44%, respectively. In this group too, 7(35%) patients proceeded to SCT (n=5) or are in planning for transplant (n=2). Though bone marrow responses were observed across all dose levels in these patients, the 3 mg/kg appeared to be more favourable at this early stage, indicating the use of this dose for further trials. Dr. Petri Bono, Chief Medical Officer of Faron, said, "Achieving this milestone underscores our commitment to addressing the urgent needs of MDS patients. These results support ongoing positive and pivotal discussions with regulatory authorities. We are dedicated to advancing bexmarilimab through clinical development into phase III, with the goal of offering new hope to patients suffering from HR-MDS." Favourable immune activation with 3 mg/kg bexmarilimab dose According to new data to be presented at EHA, bexmarilimab showed CLEVER-1 target engagement in both blood and bone marrow across all doses with no indication of accumulation with repeated dosing. Favourable activation of both the adaptive and innate immune system indicators was seen in r/r HR-MDS and frontline MDS with 3 mg/kg bexmarilimab and azacitidine. The combination was well-tolerated in all patients with HR-MDS. The details of the oral presentation are as follows: Presentation title: Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Results from the Ph1/2 BEXMAB Study Session: Oral presentation Presenter: Dr. Mika Kontro, MD, PhD Date and Time: 15 June 2025 11:00 - 12:15 CEST Location: Milan, Italy Abstract no: S178 Faron Pharmaceuticals remains committed to accelerating the clinical development of bexmarilimab for patients with high-risk myeloid malignancies and anticipates initiating preparations for a Phase III registrational trial in the second half of 2025, following discussions with the FDA. For more information, please contact: IR Partners, Finland(Media)Riina TuominenKare Laukkanen +358 44 313 50 553 9535 / +44 7 469 766 FINN Partners, US(Media) Alyssa Paldo +1 847 791-8085 Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner +44 (0) 207 213 0880 Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä +358 (0)40 555 4727+358 (0)50 553 8990 About BEXMABThe BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes. About bexmarilimabBexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals LtdFaron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at XXXX SOURCE: Faron Pharmaceuticals View the original press release on ACCESS Newswire Melden Sie sich an, um Ihr Portfolio aufzurufen.


Health Line
a day ago
- Health Line
How to Get Rid of Pink Eye Fast
Pink eye will usually go away on its own in about 1 to 2 weeks. In some cases you may be able to speed up your recovery with prescribed eye drops. Key takeaways Pink eye typically takes 1-3 weeks to clear up if viral, and 2-5 days if bacterial, though bacterial cases can be shortened with prescribed antibiotic eye drops. Antibiotic eye drops are only effective for bacterial pink eye and will not help viral, allergic, or irritant causes of pink eye. The condition is highly contagious and can spread as long as the eye appears pink and continues producing discharge, lasting up to 10 days for bacterial cases or around two weeks for viral cases. You wake up in the morning and open your eyes… at least you try to. One eye seems to be stuck shut, and the other feels like it's rubbing against sandpaper. You've got pink eye. But you also have a life and need to feel better fast. Keep reading for a fast-acting pink eye treatment plan, plus ways to keep others from getting it. Quick-acting treatments First step: Is it bacterial? To help you treat your pink eye the fastest, it's important to make your best guess as to what type you have. There are four common causes of pink eye: viral bacterial allergic irritant Viral is the most common, followed by bacterial. Viral basically means you have a cold in your eye — in fact, you'll often have it along with a cold or upper respiratory infection. Bacterial pink eye often occurs along with an ear or strep infection. It usually causes a lot more mucus and irritation than other pink eye causes. If you're having bacterial pink eye symptoms, the fastest way to treat them is to see your doctor. Your doctor can prescribe antibiotic eye drops. According to a review from the Cochrane Database of Systematic Reviews, using antibiotic eyedrops can shorten the duration of pink eye. Antibiotic eyedrops can shorten the duration of bacterial pink eye It's important to note a few things here. First, your pink eye will probably go away on its own, even if it's bacterial. If you have bacterial pink eye and you're looking for the fastest way to get rid of it, eye drops can help. Note: Antibiotic eye drops aren't going to help the other causes — viral, allergic, or irritant. This is because in those cases, bacteria isn't the reason you have pink eye. Second step: Soothe your eye(s) If you have pink eye in only one eye, your goal is to treat the affected eye without infecting the other eye. If your other eye gets infected, that will extend the length of the illness. Keep anything you use on the affected eye away from the other eye. Also, wash your hands as much as possible, especially after you touch your eye. Steps you can take to help your eye feel better include: Place a warm, damp washcloth over your affected eye. Leave it on for a few minutes. This should help to loosen any stuck-on gunk from your eye so it can open more easily. Wash your hands and use a new damp washcloth on the other eye if both of your eyes are affected. Apply lubricating eye drops, usually labeled 'artificial tears,' to each eye. Don't let the tip of the eye dropper touch your eye. If you do, throw it away because it's contaminated. Wash your hands after applying eye drops. Take over-the-counter pain relievers like ibuprofen or acetaminophen. These steps can help minimize irritation so your body can keep fighting whatever is causing your pink eye. Third step: Don't let anyone else get it Pink eye is highly contagious. Because you're trying to get rid of it fast, you don't want to give it to someone else and then get it right back after your first round resolves. To do this, practice some eye hygiene tips: Change your pillowcase and sheets every day. Use a clean towel every day. Wash your hands after you come in contact with potentially contaminated items and after you touch your eyes. Toss contact lenses that may have come in contact with your eyes as you were getting pink eye. Toss mascara and clean eye makeup brushes with soap and water to prevent recontamination. Don't share anything that touches your eyes (like mascara or eyedrops) with others. How to treat pink eye in newborns Newborns can get pink eye, usually anywhere from 1 day to 2 weeks after birth. Sometimes, this is due to an outside cause like infection or a blocked tear duct. Other times, a mom may have accidentally exposed her baby to bacteria or viruses when the baby passed through her birth canal. Examples include chlamydia, genital herpes, or gonorrhea. Because your baby is so new to the world, it's best to go straight to the doctor when they have pink eye symptoms. A doctor can examine the eye and recommend treatments, such as: applying antibiotic eye drops or ointments applying warm compresses to the eyes to reduce swelling flushing the eyes with a saline solution to reduce excess mucus and pus buildup If a newborn has an eye infection due to the bacteria that cause gonorrhea, they may need intravenous (IV) antibiotics. This type of infection can be serious and lead to permanent eye damage if left untreated. What not to do if you have pink eye If you're googling pink eye remedies, you've probably come across some wild suggestions. Most of them will only irritate your eyes and potentially make pink eye worse. Here are some things to avoid: Using anti-redness eye drops. They won't soothe your eye and they could make your condition worse. Using any kind of herbs or foods applied to the eye. They aren't sterile or medical grade. Until doctors specifically approve them to treat pink eye, stay away from these. If you've read something you're curious to try, check with your doctor's office first. You could save yourself from some potential eye damage and discomfort. When to see a doctor Not everything that looks like pink eye is pink eye. Plus, sometimes you can have a really bad case that requires medical attention. See your doctor if you have the following symptoms: increased sensitivity to light intense eye pain problems seeing significant amounts of pus or mucus coming out of your eye If you've tried at-home treatments for a week and your symptoms are getting worse instead of better, see an eye doctor. See a doctor right away if you think you have measles Pink eye can be a manifestation of measles. It may happen before you see a measles rash, or you can have both the rash and eye symptoms. While vaccinations have made measles less common, doctors have reported cases in the United States. Signs your pink eye could be related to measles include: You haven't been vaccinated, and there's an outbreak in the area. You also have symptoms like a very high fever and a red, blotchy rash. You're very sensitive to all light, including indoor light. Measles can permanently damage the eyes. If you suspect your pink eye may be measles-related, see an eye doctor right away. Frequently asked questions Can pink eye go away in three days? If your pink eye is viral, it can take 1-3 weeks for it to clear up. If it's bacterial, it can get better within 2-5 days without treatment, though sometime can also take a few weeks. Treatment with antibiotics can speed this up. How long is pink eye contagious? Pink eye is contagious as long as the affected eye appears pink, produces discharge and continue to tear. If it's bacterial, this can be up to 10 days, but less with antibiotics. Viral pink eye can be contagious for around two weeks. Is there a way to get rid of pink eye overnight? There isn't a way to help pink eye resolve this quickly. Even in bacterial cases with antibiotic treatment, it would still take more than 24 hours to get better.


Washington Post
a day ago
- Washington Post
Dutch Princess Amalia undergoes surgery after breaking arm in horse riding fall
THE HAGUE, Netherlands — The heir to the Dutch throne, Princess Amalia, was recovering in a hospital Wednesday after undergoing surgery to one of her arms that she broke a day earlier when she fell off her horse, the Royal House announced. The 21-year-old, formally known as the Princess of Orange, sustained the injury on Tuesday and underwent surgery the same evening at the University Medical Center Utrecht hospital, according to a Royal House statement.